Atossa Therapeutics, Inc.
ATOS · NASDAQ
Market closed$2.49$0.100000 (+4.18%)After hours $2.45 · -1.61%
Key statistics
Previous close$2.39
Open$2.34
Day high$2.49
Day low$2.27
52-week high$19.35
52-week low$1.70
Market cap21.44M
Volume47.87K
Average volume154.49K
P/E ratio-0.73
Forward P/E—
EPS-3.42
Dividend yield0.00%
Market context
Why it moved
ATOS shares moved higher amid broader momentum in European technology stocks, potentially boosted by news of Airbus migrating sensitive systems away from US cloud providers to European infrastructure, increasing investor interest in European IT services companies like Atos.
What is happening
Recent company-specific developments and publisher coverage.
PR Newswire · June 12, 2026Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross ProceedsTradingView · June 11, 2026Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 MillionStock Titan · June 11, 2026Biotech Atossa targets up to $16.5M to fund clinical workInvesting.com · June 11, 2026Atossa Therapeutics stock tumbles on $4.5M stock offeringPR Newswire · May 27, 2026Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 TrialPR Newswire · May 8, 2026Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateStocktwits · May 4, 2026ATOS Stock Jumps 8% Today – An FDA Designation Draws Investor Cheer For Atossa TherapeuticsStocktwits · March 25, 2026ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug Benzinga · July 7, 2026Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12 Mt Newswire · June 11, 2026Atossa Therapeutics Launches $16.5 Million Registered Direct Offering Benzinga · June 11, 2026Atossa Therapeutics Enters Securities Purchase Agreement With Institutional Investors For 1,363,638 Shares Benzinga · May 20, 2026Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular Disease Benzinga · May 14, 2026Atossa Therapeutics To Host Virtual KOL Event Focused On Evolving Clinical And Translational Data Supporting Development Of (Z)-Endoxifen As Potential Next-Gen Endocrine Therapy Backbone Across Multiple ER-Positive Breast Cancer Settings Benzinga · May 8, 2026Atossa Therapeutics Q1 EPS $(1.11) Misses $(0.94) Estimate Benzinga · May 4, 2026Atossa Therapeutics Announces FDA Rare Pediatric Disease Designation To (Z)-endoxifen For The Treatment Of McCune-Albright Syndrome In Females Benzinga · April 10, 2026Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24